Compare DAKT & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | DRUG |
|---|---|---|
| Founded | 1968 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 707.1M |
| IPO Year | 1996 | 2020 |
| Metric | DAKT | DRUG |
|---|---|---|
| Price | $20.13 | $71.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $124.00 |
| AVG Volume (30 Days) | ★ 602.4K | 82.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $608,932,000.00 | N/A |
| Revenue This Year | $13.76 | N/A |
| Revenue Next Year | $7.35 | N/A |
| P/E Ratio | $28.07 | ★ N/A |
| Revenue Growth | ★ 6.89 | N/A |
| 52 Week Low | $10.95 | $23.18 |
| 52 Week High | $28.27 | $123.75 |
| Indicator | DAKT | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 30.28 | 35.56 |
| Support Level | $18.53 | $49.47 |
| Resistance Level | $20.50 | $91.00 |
| Average True Range (ATR) | 1.12 | 4.55 |
| MACD | -0.75 | -1.24 |
| Stochastic Oscillator | 0.59 | 9.05 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.